Teva Pharmaceutical Industries Ltd to Post Q1 2019 Earnings of $0.73 Per Share, Oppenheimer Forecasts (TEVA)

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) – Analysts at Oppenheimer dropped their Q1 2019 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a report issued on Sunday, February 10th. Oppenheimer analyst E. Rajavelu now anticipates that the company will post earnings of $0.73 per share for the quarter, down from their previous forecast of $0.75. Oppenheimer has a “Hold” rating on the stock. Oppenheimer also issued estimates for Teva Pharmaceutical Industries’ Q2 2019 earnings at $0.60 EPS.

Several other research analysts have also recently weighed in on TEVA. Wells Fargo & Co set a $23.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Wednesday, October 17th. Maxim Group restated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, November 1st. Royal Bank of Canada set a $22.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, November 2nd. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the stock an “underperform” rating in a research report on Friday, November 2nd. Finally, Morgan Stanley upgraded shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $20.00 to $27.00 in a research report on Monday, November 5th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $22.98.

TEVA stock opened at $17.63 on Tuesday. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. Teva Pharmaceutical Industries has a fifty-two week low of $14.59 and a fifty-two week high of $25.96. The company has a market capitalization of $19.44 billion, a P/E ratio of 4.49, a P/E/G ratio of 5.83 and a beta of 1.46.

In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 1,643 shares of the company’s stock in a transaction on Wednesday, January 2nd. The shares were sold at an average price of $15.70, for a total transaction of $25,795.10. Following the completion of the sale, the vice president now owns 13,469 shares in the company, valued at approximately $211,463.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.43% of the company’s stock.

Several institutional investors have recently modified their holdings of TEVA. FMR LLC grew its holdings in shares of Teva Pharmaceutical Industries by 19.1% in the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock valued at $527,341,000 after buying an additional 3,921,785 shares during the period. Polaris Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 4.4% in the 4th quarter. Polaris Capital Management LLC now owns 10,342,980 shares of the company’s stock valued at $159,489,000 after buying an additional 431,942 shares during the period. Alliancebernstein L.P. grew its holdings in shares of Teva Pharmaceutical Industries by 32.0% in the 3rd quarter. Alliancebernstein L.P. now owns 9,454,839 shares of the company’s stock valued at $203,657,000 after buying an additional 2,291,171 shares during the period. Northern Trust Corp grew its holdings in shares of Teva Pharmaceutical Industries by 2.7% in the 4th quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock valued at $103,125,000 after buying an additional 175,173 shares during the period. Finally, TIAA CREF Investment Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 4.4% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 6,335,449 shares of the company’s stock valued at $136,466,000 after buying an additional 264,693 shares during the period. Institutional investors own 62.11% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Further Reading: Asset Allocation, Balancing Your Investments

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit